An interventional study of Omnipod 5 or Medtronic 780G and My HypoCOMPaSS Education in Diabetes Mellitus, Type 1, sponsored by Milton S. Hershey Medical Center. Recruiting at 8 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 90th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 65 that started in 2025, is one of 614 with no phase, reaches primary completion later than 230 of the 256 other live ones, and was the 1,290th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 31–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 5–40
Stanford University · Sites in United States
Ages 18–60 · Healthy volunteers
Wayne State University · Sites in United States
Ages 16–20
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,458 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 206 · Phase 2 267 · Phase 3 167 · Phase 4 74
First in 1983; this study’s year is marked. 65 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 324 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 1,242 interventional studies, 63 across the 203 observational. Of the 1,118 that completed or were terminated, 563 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,458 have an industry lead sponsor. The 10 most frequent:
Milton S. Hershey Medical Center is the lead sponsor of 493 studies on the registry; 60 are open to participants now.
Of its 58 completed or terminated interventional studies of FDA-regulated products, 46 (79%) have results posted.
Milton S. Hershey Medical Center has 3 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
115 of the studies in Diabetes Mellitus, Type 1 with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT06334133Phase 3vTv TherapeuticsCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | 2027-04 |
| NCT07056699Phase 3The University of Texas Health Science Center at San AntonioSGLT2i, Pioglitazone, and Ketone Production in T1D | 2027-06-01 |
Add all 115 to your calendar (.ics) → With an account.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the CLEAR study is to determine the effect on counterregulatory responses (CRR) of intervening (by attempting to strictly avoid hypoglycemia) to improve awareness of hypoglycemic symptoms among adults with type 1 diabetes (T1D) who have impaired awareness of hypoglycemia (IAH). IAH affects 20-25% of adults with T1D, and rises with increasing duration of T1D.
Individuals with IAH exhibit blunted symptomatic and CR hormonal responses to hypoglycemia and, as such, have an impaired ability to respond to hypoglycemia. Thus, rates of severe hypoglycemia are up to 6-fold greater in those affected. Intensive management of T1D is necessary in preventing long-term complications, but can be complicated by recurrent episodes of hypoglycemia which lead to and sustain the CRR deficits of IAH. Technologies such as continuous glucose monitoring (CGM) and hybrid closed-loop (HCL) systems can reduce severe hypoglycemia (and also may reduce IAH) but the ability of technology to reverse impaired CRR (as assessed with experimental hypoglycemia clamp) remains unclear. Behavioral and psycho-educational interventions targeting knowledge/skills gaps, as well as particular cognitions and behaviors driving recurrent hypoglycemia, can also reduce severe hypoglycemia and improve awareness. No studies have compared technology with such behavioral interventions in terms of assessing their impact on IAH or the CRR (as a primary outcome). Unanswered questions include the degree of reduction in hypoglycemia required to restore awareness. Furthermore, participants may respond to different interventions according to their characteristics. For example, it remains unclear whether older individuals benefit from such interventions since they usually are excluded from studies. Therefore, there is an urgent need to determine effective interventions that can reverse IAH in a large representative population of adults with T1D and IAH. The investigators propose to study the effect of specific interventions aimed at restoring
The study will use a Sequential Multiple Assignment Randomized Trial (SMART) design. At baseline, all participants who are HCL naïve will be randomized to HCL or Usual Care (UC) plus brief education (My HypoCOMPaSS) with a follow-up of two years. UC will consist of real-time continuous glucose monitoring (CGM) and insulin delivery via pump or multiple daily injections. Participants who fail to increase their CRR at 12 months will be randomized, or assigned, to a second intervention consisting of a small-group educational program focusing on motivations and unhelpful cognitions acting as barriers to hypoglycemia avoidance (HARPdoc). At baseline, all participants who are HCL non-naïve will be randomized to optimized HCL or HCL plus My HypoCOMPaSS; those with non-responsive CRR at 12 months will be randomized to either continue HCL (on the basis they need a longer period to reverse impaired CRR and total symptomatic responses) or to the HARPdoc intervention. Participants randomized to an HCL device are expected to wear the device continually, as well as a CGM. The My HypoCOMPaSS education requires 4-5 hours of training, whereas, the HARPdoc education requires four training sessions of seven hours each during weeks 1,2,3, and 6.
The specific aims and hypotheses are as follows:
Aim 1: To determine the effect on CRR (epinephrine increase ≥ 125 pg/ml over baseline) and total symptom responses (Towler Questionnaire increase ≥ 20% over baseline) during a hyperinsulinemic-hypoglycemic clamp procedure (glucose \< 50 mg/dl) after 12 months of HCL versus Usual Care plus My HypoCOMPaSS Educational Intervention among adults with T1D and IAH who have never used HCL therapy previously.
Hypothesis 1: At 12 months, those allocated to Usual Care plus My HypoCOMPaSS will be more likely to have improved CRR and total symptomatic responses than those allocated to HCL.
Aim 2: To determine the effect on CRR and total symptom responses at 12 months of HCL plus My HypoCOMPaSS versus HCL alone among adults with T1D and IAH who are currently using HCL therapy prior to entering the study.
Hypothesis 2: At 12 months, those allocated to HCL plus My HypoCOMPaSS will be more likely to have improved hypoglycemic awareness and improved CRR than those using HCL alone.
Aim 3: To determine the durability of effect over 24 months of the intervention that improves CRR at 12 months among adults with type 1 diabetes and IAH at baseline.
Hypothesis 3: At 24 months, CRR will improve further among those who had restored CRR at 12 months.
Aim 4. To determine the effect on hypoglycemic awareness (Towler Questionnaire increase ≥ 20% over baseline) and CRR (epinephrine increase ≥ 125 pg/ml over baseline) during a hyperinsulinemic hypoglycemic clamp procedure at 24 months of an in-depth educational program (HARPdoc), initiated throughout months 12-24, among adults with T1D and IAH at baseline, for whom the intervention allocated at baseline did not restore CRR at 12 months.
Hypothesis 4: At 24 months, those allocated to HARPdoc for months 12-24 months will be more likely to have improved hypoglycemic awareness and CRR than those who continue with the therapy allocated at baseline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of adrenalectomy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hybrid closed loop device over a 24-month period for individuals currently not using a hybrid closed loop device
Device: Omnipod 5 or Medtronic 780G
Hybrid closed loop device over a 12-month period for individuals currently not using a hybrid closed loop device, and then a hybrid closed loop device for an additional 12 months
Device: Omnipod 5 or Medtronic 780G
Hybrid closed loop device over a 12-month period for individuals currently not using a hybrid closed loop device, then a hybrid closed loop device plus HARPdoc education for an additional 12 months
Device: Omnipod 5 or Medtronic 780G · Behavioral: HARPdoc Education
Usual Care and My HypoCOMPaSS education over 12 months for individuals currently not using a hybrid closed loop device, then hybrid closed loop device for 12 months
Device: Omnipod 5 or Medtronic 780G · Behavioral: My HypoCOMPaSS Education
Usual Care and My HypoCOMPaSS education over 24 months for individuals currently not using a hybrid closed loop device
Behavioral: My HypoCOMPaSS Education
Hybrid closed loop device over a 24-month period for individuals currently using a hybrid closed loop device
Device: Omnipod 5 or Medtronic 780G
Hybrid closed loop device over a 12-month period for individuals currently using a hybrid closed loop device, and then a hybrid closed loop device for an additional 12 months
Device: Omnipod 5 or Medtronic 780G
Hybrid closed loop device over a 12-month period for individuals currently using a hybrid closed loop device, then a hybrid closed loop device plus HARPdoc education for an additional 12 months
Device: Omnipod 5 or Medtronic 780G · Behavioral: HARPdoc Education
Hybrid closed loop device and My HypoCOMPaSS education over 12 months for individuals currently using a hybrid closed loop device, then hybrid closed loop device for 12 months
Device: Omnipod 5 or Medtronic 780G · Behavioral: My HypoCOMPaSS Education
Hybrid closed loop device and My HypoCOMPaSS education over 12 months for individuals currently using a hybrid closed loop device, then hybrid closed loop device plus My HypoCOMPaSS eduction + HARPdoc education for 12 months
Device: Omnipod 5 or Medtronic 780G · Behavioral: My HypoCOMPaSS Education · Behavioral: HARPdoc Education
Hybrid closed loop device plus My HypoCOMPaSS education over a 24-month period for individuals currently using a hybrid closed loop device
Device: Omnipod 5 or Medtronic 780G · Behavioral: My HypoCOMPaSS Education
Omnipod 5 and Medtronic 780G are hybrid closed loop devices that provide automated insulin delivery.
My HypoCOMPaSS is a brief, standardized psycho-educational program delivered in small groups. Facilitated discussions focus on advocating rigorous avoidance of hypoglycemia while maintaining time in target glycemic range.
The HARPdoc program targets cognitions around hypoglycemia that act as barriers to hypoglycemia avoidance and recovery of awareness using motivational and cognitive approaches, delivered by diabetes educators, trained and supported by a clinical psychologist, in small group format.
epinephrine (pg/ml)
a change in epinephrine (pg/ml) that exceeds 125 pg/ml between (1) 12 months and baseline, and (2) 24 months and baseline
Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months
Towler questionnaire
the Towler questionnaire consists of 12 questions each on a 0-6 Likert scale; a change in the questionnaire that exceeds 20% between (1) 12 months and baseline, and (2) 24 months and baseline
Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months
geometric mean of plasma glucagon
geometric mean of plasma glucagon
Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months
geometric mean of plasma pancreatic polypeptide
geometric mean of plasma pancreatic polypeptide
Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months
geometric mean of plasma free fatty acids
geometric mean of plasma free fatty acids
Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months
glucose infusion rate
glucose infusion rate
Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months
HbA1c
glycated hemoglobin
Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months
% of time with sensor hypoglycemia <70 mg/dL
% of time with hypoglycemia \<70 mg/dL determined from the continuous glucose monitor (CGM) sensor
Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months
% of time with sensor hypoglycemia <54 mg/dL
% of time with hypoglycemia \<54 mg/dL determined from the continuous glucose monitor (CGM) sensor
Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months
number of hypoglycemia events
number of hypoglycemia events determined from the continuous glucose monitor (CGM) sensor
Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months
% time with sensor glucose in range
% time with glucose in range determined from the continuous glucose monitor (CGM) sensor
Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months
sensor glucose coefficient of variation
sensor glucose coefficient of variation determined from the continuous glucose monitor (CGM) sensor
Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months
sensor use as the average numbers of days per week
sensor use as the average number of days per week determined from the continuous glucose monitor (CGM) sensor
Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months
glycemia risk index
glycemia risk index determined from the continuous glucose monitor (CGM) sensor
Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months
Trail Making Test - Part B
amount of time required to complete the Trail Making Test - Part B
Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months
Four Choice Reaction Time
Four Choice Reaction Time, which measures reaction time and motor coordination
Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months
sleep duration
sleep duration determined from an activity monitor smartwatch
Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
sleep quality
sleep quality determined by an activity monitor smartwatch
Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
24-hour step count
24-hour step count determined by an activity monitor smartwatch
Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
exercise bouts
exercise bouts determined by an activity monitor smartwatch
Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
resting heart rate
resting heart rate determined by an activity monitor smartwatch
Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
heart rate during exercise
heart rate during exercise determined by an activity monitor smartwatch
Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
heart rate variability
heart rate variability determined by an activity monitor smartwatch
Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
Hypo-METRICS questionnaire
Hypo-METRICS questionnaire, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia
Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
Hypoglycemic Confidence Scale
Hypoglycemic Confidence Scale, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia, the range is 0 through 27 and higher scores correspond to higher confidence
Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
Hypoglycemia Fear Survey-II
Hypoglycemia Fear Survey-II, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia
Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
Attitudes to Awareness of Hypoglycaemia
Attitudes to Awareness of Hypoglycaemia, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia
Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
Type 1 Diabetes Distress Scale
Type 1 Diabetes Distress Scale, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia
Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
Diabetes Self-Management Questionnaire
Diabetes Self-Management Questionnaire, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia
Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
Diabetes Management Experiences Questionnaire
Diabetes Management Experiences Questionnaire, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia
Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
PROMIS Sleep Disturbance - Short Form 8a
PROMIS Sleep Disturbance - Short Form 8a
Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
Hospital Anxiety and Depression Scale
Hospital Anxiety and Depression Scale
Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months, the range is 0 through 42 and higher scores correspond to higher anxiety and depression
12-Item Hypoglycemia Impact Profile
12-Item Hypoglycemia Impact Profile, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia
Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
EQ-5D-5L
EQ-5D-5L, a quality-of-life scale with 5 dimensions
Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months
device-related adverse events
device-related adverse events
Time frame: throughout the duration of the 24 months of follow-up
severe hypoglycemic events, self-reported on a CLEAR data collection form
severe hypoglycemic events, self-reported on a CLEAR data collection form
Time frame: throughout the duration of the 24 months of follow-up
diabetic ketoacidosis (DKA) events
diabetic ketoacidosis (DKA) events
Time frame: throughout the duration of the 24 months of follow-up
number of participants with hospitalizations
number of participants with hospitalizations
Time frame: throughout the duration of the 24 months of follow-up
number of participants with emergency room (ER) visits
number of participants with emergency room (ER) visits
Time frame: throughout the duration of the 24 months of follow-up
major adverse cardiovascular events (MACE)
major adverse cardiovascular events (MACE)
Time frame: throughout the duration of the 24 months of follow-up
all-cause mortality
all-cause mortality
Time frame: throughout the duration of the 24 months of follow-up
Plan to share: Yes — The release data sets will be stored at the NIDDK Central Repository. The release data sets will de-identified, i.e., they will not contain names, social security numbers, addresses, phone numbers, health care records, and/or similar protected health information. In addition, the release data sets will have an anonymous study ID that is linked to an individual only in the participant records at the Biostatistics Research Center at the Penn State College of Medicine.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: The timeline for data sharing from the Impaired Awareness of Hypoglycemia Consortium will meet NIH data sharing requirements, such as one year after the Consortium investigators have published the primary manuscript. The Biostatistics Research Center at the Penn State College of Medicine will make data available after the acceptance for publication of the main findings that address the specific aims of the study.
Access criteria: Investigators external to the Consortium will be able to request the data from the NIDDK Central Repository. They will be required to show proof of their local IRB approval.
Data sharing details ↗ · repository.niddk.nih.gov
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2029, 50 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 50 months is above that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Jul 2029 → Dec 2029 and completion Jul 2029 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Milton S. Hershey Medical Center →